AgomAb Therapeutics NV (NASDAQ:AGMB) Given Average Rating of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $32.75.

Separately, HC Wainwright started coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective for the company.

AgomAb Therapeutics Trading Down 2.5%

NASDAQ AGMB opened at $12.32 on Friday. The business’s fifty day simple moving average is $11.72. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.